PDF下载 ( 1163 KB)
Recent research on liver fibrosis and cirrhosis
-
摘要:
肝硬化因其不可逆性肝细胞功能损害和门静脉高压引发的严重并发症而威胁人类健康。肝纤维化是慢性肝病向肝硬化发展的重要阶段,目前大多数研究认为在该阶段疾病尚可逆转。本文就近年肝纤维化及肝硬化的研究近况进行讨论。
-
关键词:
- 肝硬化
Abstract:Liver cirrhosis can do great harm to human health due to irreversible function impairment of hepatocytes and severe complications caused by portal hypertension.Liver fibrosis is an inevitable stage through which chronic liver disease progresses to cirrhosis.So far, most studies have demonstrated that the liver disease in fibrosis stage can be reversed.This paper reviews recent research on liver fibrosis and cirrhosis.
-
Key words:
- liver cirrhosis
-
[1]Friedman SL.Hepatic stellate cells:protean, multifunctional, andenigmatic cells of the liver[J].Physiol Rev, 2008, 88 (1) :125-172. [2]Kordes C, Sawitza I, Muller-Marbach A, et al.CD133+hepaticstellate cells are progenitor cells[J].Biochem Biophys Res Com-mun, 2007, 352 (2) :410-417. [3]Zeisberg M, Yang C, Martino M, et al.Fibroblasts derive from hepato-cytes in liver fibrosis via epithelial to mesenchymal transition[J].J Bi-ol Chem, 2007, 282 (32) :23337-23347. [4]Taura K, Miura K, Iwaisako K, et al.Hepatocytes do not undergoepithelial-mesenchymal transition in liver fibrosis in mice[J].Hepatology, 2010, 51 (3) :1027-1036. [5]Choi SS, Diehl AM.Epithelial-to-mesenchymal transitions inthe liver[J].Hepatology, 2009, 50 (6) :2007-2013. [6]Yoshiji H, Kuriyama S, Yoshii J, et al.Vascular endothelialgrowth factor and receptor interaction is a prerequisite for murinehepatic fibrogenesis[J].Gut, 2003, 52 (9) :1347-1354. [7]Bockx I, Verdrengh K, Vander Elst I, et al.High-frequency va-gus nerve stimulation improves portal hypertension in cirrhotic rats[J].Gut, 2012, 61 (4) :604-612. [8]Steib CJ, Gerbes AL, Bystron M, et al.Kupffer cell activation in nor-mal and fibrotic livers increases portal pressure via thromboxane A (2) [J].J Hepatol, 2007, 47 (2) :228-238. [9]Holland-Fischer P, Gronbaek H, Sandahl TD, et al.Kupffer cellsare activated in cirrhotic portal hypertension and not normalised byTIPS[J].Gut, 2011, 60 (10) :1389-1393. [10]Lebrec D, Sogni P, Vilgrain V.Evaluation of patients with portalhypertension[J].Baillieres Clin Gastroenterol, 1997, 11 (2) :221-241. [11]Poynard T, Munteanu M, Deckmyn O, et al.Validation of liver fi-brosis biomarker (FibroTest) for assessing liver fibrosis progression:proof of concept and first application in a large population[J].JHepatol, 2012, 57 (3) :541-548. [12]Thabut D, Imbert-Bismut F, Cazals-Hatem D, et al.Relation-ship between the Fibrotest and portal hypertension in patients withliver disease[J].Aliment Pharmacol Ther, 2007, 26 (3) :359-368. [13]Ngo Y, Benhamou Y, Thibault V, et al.An accurate definition ofthe status of inactive hepatitis B virus carrier by a combination of bi-omarkers (FibroTest-ActiTest) and viral load[J].PLoS One, 2008, 3 (7) :e2573. [14]Tsochatzis EA, Gurusamy KS, Ntaoula S, et al.Elastography forthe diagnosis of severity of fibrosis in chronic liver disease:a meta-analysis of diagnostic accuracy[J].J Hepatol, 2011, 54 (4) :650-659. [15]Roulot D, Costes JL, Buyck JF, et al.Transient elastography as ascreening tool for liver fibrosis and cirrhosis in a community-basedpopulation aged over 45 years[J].Gut, 2011, 60 (7) :977-984. [16]Vizzutti F, Arena U, Romanelli RG, et al.Liver stiffness measurementpredicts severe portal hypertension in patients with HCV-related cir-rhosis[J].Hepatology, 2007, 45 (5) :1290-1297. [17]Ran HT, Ye XP, Zheng YY, et al.Spleen stiffness and splenopor-tal venous flow:assessment before and after transjugular intrahepaticportosystemic shunt placement[J].J Ultrasound Med, 2013, 32 (2) :221-228. [18] Chinese Society of Hepatology and Chinese Society of Infectious Dis-eases, Chinese Medical Association.The Guideline of preventionand treatment for chronic hepatitis B (2010 version) [J].J ClinHepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学合肝病学分会, 感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ. [19]Mutimer DJ, Lok A.Management of HBV-and HCV-inducedend stage liver disease[J].Gut, 2012, 61 (Suppl 1) :i59-67. [20]Yokohama S, Yoneda M, Haneda M, et al.Therapeutic efficacy ofan angiotensin II receptor antagonist in patients with nonalcoholicsteatohepatitis[J].Hepatology, 2004, 40 (5) :1222-1225. [21]Abramovitch S, Dahan-Bachar L, Sharvit E, et al.Vitamin D in-hibits proliferation and profibrotic marker expression in hepatic stel-late cells and decreases thioacetamide-induced liver fibrosis in rats[J].Gut, 2011, 60 (12) :1728-1737. [22]Tugues S, Fernandez-Varo G, Munoz-Luque J, et al.Antiangio-genic treatment with sunitinib ameliorates inflammatory infiltrate, fi-brosis, and portal pressure in cirrhotic rats[J].Hepatology, 2007, 46:1919-1926. [23]Bari K, Garcia-Tsao G.Treatment of portal hypertension[J].World JGastroenterol, 2012, 18 (11) :1166-1175. [24]Steib CJ, Hennenberg M, Beitinger F, et al.Amiloride reducesportal hypertension in rat liver cirrhosis[J].Gut, 2010, 59 (6) :827-836. [25]Runyon BA.Management of adult patients with ascites due to cir-rhosis:an update[J].Hepatology, 2009, 49 (6) :2087-2107. [26]Haussinger D, Schliess F.Pathogenetic mechanisms of hepatic en-cephalopathy[J].Gut, 2008, 57 (8) :1156-1165. -
下载:
